JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The firm’s analysis suggests CagriSema is likely to deliver 25% weight loss ...

Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Recent studies have also found that GLP-1 treatments, the class of diabetes and weight loss drugs that includes Novo Nordisk’s (NVO) Ozempic and Wegovy, are linked to a lower risk of Alzheimer’s.

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity care. The company develops a long line of blockbuster glucagon-like ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...